Moderna Inc (Moderna) is a biotechnology company dedicated to developing and commercializing messenger RNA (mRNA) medicines. The company works to deliver transformative treatments for patients by using mRNA to create vaccines and therapeutics across diseases, including infectious illnesses, cancer, rare disorders, and autoimmune conditions. Moderna operates within the biotechnology and pharmaceutical sectors. Moderna’s business portfolio spans a broad range of mRNA-based products and services. The company has launched two commercial respiratory virus vaccines: Spikevax, its COVID-19 vaccine, and mRESVIA, its RSV vaccine for older adults. Moderna is also progressing its pipeline with multiple mRNA vaccines and therapeutics, including next-generation COVID vaccines, RSV vaccines for high-risk adults, seasonal flu+COVID combination vaccines, and seasonal flu vaccines. The company is active in oncology therapeutics, with individualized neoantigen therapy (INT) being developed with Merck. In addition, Moderna is pursuing rare disease therapeutics for propionic acidemia (PA) and methylmalonic acidemia (MMA), along with a norovirus vaccine. The company has developed seven modalities, including infectious disease vaccines, systemic secreted and cell surface therapeutics, cancer therapies, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. Moderna’s mRNA platform combines progress in mRNA science, delivery technologies, and manufacturing processes to produce its medicines. Its manufacturing capabilities support all stages of product development, from discovery through commercialization. The company partners with contract manufacturing organizations (CMOs) in the United States and globally. Moderna maintains strategic alliances with pharmaceutical and biotechnology companies, government agencies, academic laboratories, foundations, and research institutes. The company operates two main campuses in Massachusetts, including the Moderna Science Center (MSC) in Cambridge and the Moderna Technology Center (MTC) in Norwood. As of December 2025, the company runs manufacturing plants in the US, Canada, the UK, and Australia.

Moderna is focused on harnessing mRNA to create a new category of medicines, with research and development (R&D) initiatives spanning infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. The company is working on developing mRNA medicines for a wide range of diseases and conditions, with a significant emphasis on clinical trials to get these medicines approved. Under the R&D, the company focuses on platform development, discovery efforts, preclinical and clinical development, manufacturing technology, and digital infrastructure related to drug discovery and clinical trials. Moderna has also established a substantial intellectual property estate that includes numerous patents and patent applications related to mRNA vaccines and therapeutic development candidates, platform technologies, and delivery systems. In FY2025, the company spent US$3,132 million on its R&D activities, which declined 31% YoY. The pipeline includes various mRNA medicines in development for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. Major technology alliances include collaborations with Merck, IAVI, BMGF, NIAID, BARDA, NIH, and Immatics. Some of the pipeline drugs in phase III include mRNA-1010 as a flu vaccine; mRNA-1345 as an RSV vaccine for patients of 18 to 59 years at high risk; mRNA-1083 as a Flu + COVID vaccine; mRNA-1647 as a CMV vaccine; mRNA-1403 as a Norovirus vaccine; and mRNA-4157 to treat Adjuvant melanoma, Adjuvant NSCLC, and Adjuvant NSCLC post neoadjuvant treatment.